

## Construction and Production of Foxp3- Fc (IgG) DNA Vaccine/Fusion Protein

Neda Mousavi Niri <sup>1</sup>, Arash Memarnejadian <sup>2</sup>, Jamshid Hadjati <sup>3\*</sup>, Mohammad Reza Aghasadeghi <sup>2</sup>, Mehdi Shokri <sup>2</sup>, Yones Pilehvar-soltanahmadi <sup>1</sup>, Abolfazl Akbarzadeh <sup>4</sup>, and Nosratollah Zarghami <sup>1,5\*</sup>

1. Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran

2. Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran

3. Department of Immunology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

4. Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran

5. Department of Clinical Biochemistry, Radiopharmacy Lab, Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

## Abstract

**Background:** It seems that the success of vaccination for cancer immunotherapy such as Dendritic Cell (DC) based cancer vaccine is hindered through a powerful network of immune system suppressive elements in which regulatory T cell is the common factor. Foxp3 transcription factor is the most specific marker of regulatory T cells. In different studies, targeting an immune response against regulatory cells expressing Foxp3 and their removal have been assessed. As these previous studies could not efficiently conquer the suppressive effect of regulatory cells by their partial elimination, an attempt was made to search for constructing more effective vaccines against regulatory T cells by which to improve the effect of combined means of immunotherapy in cancer. In this study, a DNA vaccine and its respective protein were constructed in which Foxp3 fused to Fc(IgG) can be efficiently captured and processed by DC via receptor mediated endocytosis and presented to MHCII and I (cross priming).

**Methods:** DNA construct containing fragment C (Fc) portion of IgG fused to Foxp3 was designed. DNA construct was transfected into HEK cells to investigate its expression through fluorescent microscopy and flow cytometry. Its specific expression was also assessed by western blot. For producing recombinant protein, FOXP3-Fc fusion construct was inserted into pET21a vector and consequently, *Escherichia coli* (*E. coli*) strain BL21 was selected as host cells. The expression of recombinant fusion protein was assayed by western blot analysis. Afterward, fusion protein was purified by SDS PAGE reverse staining.

**Results:** The expression analysis of DNA construct by flow cytometry and fluorescent microscopy showed that this construct was successfully expressed in eukaryotic cells. Moreover, the Foxp3-Fc expression was confirmed by SDS-PAGE followed by western blot analysis. Additionally, the presence of fusion protein was shown by specific antibody after purification.

**Conclusion:** Due to successful expression of Foxp3-Fc (IgG), it would be expected to develop vaccines in tumor therapies for removal of regulatory cells as a strategy for increasing the efficiency of other immunotherapy means.

*Avicenna J Med Biotech* 2016; 8(2): 57-64

**Keywords:** FOXP3 protein, Fusion protein, Immunoglobulin G (IgG)

## Introduction

The immune system exploits a network of central and peripheral tolerance mechanisms to discriminate between self and non-self. One of the main components of this network is CD4+CD25+regulatory T cells (T reg) whose function is to suppress immune responses <sup>1</sup>. As well as CD25, other markers such as GITR,

CTLA-4, CD133 and OX-40 are overexpressed on T reg cells but their expression is not as specific as CD25 on regulatory T cells <sup>2</sup>. A transcription factor called FoxP3, a member of the fork head family of transcription factors, is specifically expressed by T regs. Regulatory T cells control the immune response either by

\* Corresponding authors:  
Jamshid Hadjati, Ph.D.,  
Department of Immunology,  
Faculty of Medicine, Tehran  
University of Medical Sciences,  
Tehran, Iran

Nosratollah Zarghami, Ph.D.,  
Department of Medical  
Biotechnology, Faculty of  
Advanced Medical Sciences and  
Department of Clinical  
Biochemistry and Laboratory  
Sciences, Faculty of Medicine,  
Tabriz University of Medical  
Sciences, Tabriz, Iran  
Tel: +98 41 33355788

E-mail:  
zarghami@tbzmed.ac.ir

Received: 10 Jun 2015

Accepted: 28 Oct 2015

their direct contact with the immune cells or with the secretion of soluble factors. The importance of regulatory cells in maintaining self-tolerance is illustrated by deficiency in their content and function in many autoimmune diseases<sup>3</sup>. Evidences from mouse model systems and cancer patients indicate that regulatory T cells affect anti-tumor responses in tumor-bearing individuals<sup>2-7</sup>. Two sets of observations also implicate T reg in suppression of tumor immunity. First, the numbers of T reg increased at the tumor sites of cancer patients correlated with disease progression. Second, depletion of regulatory T cells in mice enhances antitumor immunity and reduces tumor growth<sup>3</sup>. In spite of that, in recent clinical trial, elimination of T reg in renal cancer patients using an interleukin 2(IL2)/diphtheria toxin fusion product (ONTAK) led to enhanced vaccine-induced anti-tumor immune responses. Therefore, elimination of T reg could represent an important adjunct to cancer immunotherapy<sup>8</sup>.

The only gene product known to be exclusively expressed in T reg of mice is FoxP3. FoxP3 is an intracellular factor which its expression is not only in CD4+CD25+T cells but also in CD4+CD25<sup>low/-</sup> T reg, as well as, subsets of CD8+T cells that exhibit immune-suppressive properties. Thus, targeting FoxP3 offers distinct advantages over targeting CD25 to eliminate immune suppressive cells *in vivo*<sup>3</sup>. Since FoxP3 is an intracellular product, FoxP3 expressing T regs cannot be destroyed using monoclonal antibodies<sup>9</sup>. CD8+ Cytotoxic T cells (CTL) could recognize cellular products combined with MHCI on cell surface. FoxP3 laboring cells could be targeted by CTL in the same way<sup>10</sup>.

Generally, different means have been exploited in T reg suppression by researchers such as chemical drugs<sup>9,11,12</sup>, anti CD25 monoclonal anti body<sup>13,14</sup>, immunotoxins [Denileukin diftitox (ONTAK) and LMB-2 (single chain fragment variable anti-tac fused with bacterial *Pseudomonas exotoxin A*)]<sup>1,8,15</sup> and anti T reg vaccination targeting FoxP3<sup>3</sup>. To date, there have been several strategies in targeting FoxP3 for T reg suppression<sup>3,9,16</sup>. In a project by Generali et al, T regs were modulated by letrozole which is one of Aromatase inhibitors and impairs FoxP3 signaling<sup>9</sup>. In 2007, Nair *et al* showed that depletion of regulatory T cells using dendritic cells pulsed with mRNA of FoxP3 could enhance effect of therapeutic anticancer vaccination<sup>3</sup>. Overall, depletion of T regs in transgenic manner also improves therapeutic anticancer immune properties of effector cells<sup>17</sup>.

Antigen immunogenicity can be augmented in their fusion with fragment C (Fc) of immunoglobulin heavy chain leading to antigen-Fc fusion protein. The antigen-Fc fusion protein attaches to Fc receptors on the surface of antigen expressing cells (APCs) and antigen can be targeted by these cells in mammalian cells<sup>18</sup>. In some researches, fusion of fragment C of immunoglobulin G (IgG) to different antigens such as tumor

antigens could stimulate higher immune responses compared to antigens alone<sup>19</sup>. You *et al* showed that fusion of hepatitis B antigen to Fc (IgG) in a DNA vaccine format led to enhanced capture and presentation of antigen by dendritic cell. The respective fusion protein produced by this DNA vaccine could induce B cell response more effectively. As well as its efficient receptor-mediated endocytosis by dendritic cell, it could also be better presented on MHCI and MHCII. Totally, the antigen-Fc fusion caused considerable increase in antigen specific responses of CD4+T cell, CD8+CTL and B cell<sup>20</sup>. Apart from enhancing the antigenic stimulation, Ig(Fc) fusion has been shown to possess other advantages, too. Chemokine/cytokine-Ig fusion presents the advantages of divalent affinity, non-cytolytic effect and long *in vivo* half-life with conserved activity of both proteins<sup>21,22</sup>. The main objective of this study was cloning and expression of recombinant vectors containing FoxP3-IgG2Fc with the purpose of DNA vaccine and recombinant protein production (As prime/boost vaccination regimen in future studies) by a simple one step procedure and evaluation of their proper work *ex vivo* and *in vitro*, respectively.

## Materials and Methods

### Plasmids and bacterial strains

pEGFPN1-FoxP3 and pET24a-FoxP3 plasmids which were previously constructed by our research group were truncated FoxP3 genes cloned in pEGFPN1 and pET24a vectors, respectively. Truncated FoxP3 lacks a polypeptide segment called nuclear localization signal and its shortage leads to impaired functional properties of FoxP3. pIRES2-EGFP-IL18-Fc(IgG) was a gift from another research group (22). *Escherichia coli* (*E. coli*) strains, DH5α and BL21 (DE3), and plasmids, pIRES2-EGFP and pET21a, were obtained from National Recombinant Gene Bank (NRGB), Pasteur Institute of Iran.

### Bacterial cultures

The *E. coli* strains were grown in LB broth (10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl, pH=7.0) and on LB agar with Kanamycin and Ampicilin (Sigma).

### Chemicals and enzymes

IPTG, T4 DNA ligase and *Pfu* DNA polymerase were purchased from Fermentase (Lithuania). Chemicals were obtained from Merck (Germany). Restriction endonucleases were purchased from Enzymomics (Korea). PolyFect transfection kit was obtained from Qiagen (Germany).

### Gene amplification and cloning procedures

Truncated (1114 bp) FoxP3 fragment (corresponding to amino acids 1-363) was created by PCR amplification on previously constructed pEGFP-N1-FoxP3 plasmid, using *Nhe*I-tailed forward (5' ATAT GCTAG CGCCACCATGGCTC3'), *Bgl*II-tailed reverse (5' TA CAGATCTGGCGAACATGCGAG3') primer pairs and proofreader *Pfu* DNA polymerase (Thermo, USA)

in a thermal program of 94°C (4 min) and 30 cycles of 94°C (40 s), 55°C (40 s) and 72°C (68 s). The kozak Seq (ACCATGG) was already included in the upstream of truncated FoxP3 gene in pEGFP-N1-FoxP3 plasmid that was used as a template for PCR cloning of FoxP3 into pIRES plasmid. Also, kozak sequence was in our designed *NheI*-tailed forward primer. As it is shown in figure 1A, to construct pIRES2-EGFP-FoxP3-IgG2Fc plasmid that encoded the fusion of truncated FoxP3-IgG2Fc, amplified FoxP3 truncated gene was double digested with *NheI*/*Bgl*II enzymes and further replaced with Igk-IL18 segment in previously constructed pIRES2-EGFP-Igk-IL18-IgG2Fc plasmid. This plasmid expresses FoxP3-IgGFc fusion protein and additionally encodes for EGFP as a separate protein.

Additionally, pET21-FoxP3-IgG2Fc plasmid was constructed by PCR amplification on previously constructed pIRES2-EGFP-FoxP3-IgG2Fc plasmid, using *EcoRI*-tailed forward (5'TGGAATTCGCTCCTTCCT TGG3'), *Hind*III-tailed reverse (TATAAGCTTTAG CCCCCGAGTCC) primer pairs and proofreader *Pfu* DNA polymerase (Thermo, USA) in a thermal program of 94°C (4 min) and 30 cycles of 94°C (40 s), 56°C (40 s) and 72°C (240 s). *EcoRI*-FoxP3-IgG2Fc-*Hind*III fragment was cloned into pET21a to construct pET21-FoxP3-IgG2Fc plasmid. This plasmid encodes for T7tag-FoxP3-IgG2Fc fusion protein (Figure 1B).

Finally, the precision of cloned genes in all recombinant plasmids of pIRES2-EGFP-FoxP3-IgG2Fc and pET21-FoxP3-IgG2Fc was checked and confirmed by restriction endonuclease double digestion and commercially available sequencing services (Sequencing Lab., Pasteur Institute of Iran).




Figure 1. Cloning strategies for constructing the A) pIRES2-EGFP-FoxP3-IgG2Fc and B) pET21a-FoxP3-IgG2Fc vectors.

#### Cell line, transfection, and preparation of cell lysate

HEK-293 cell line was maintained in Dulbecco's Modified Eagle Medium (DMEM, 1x) containing 2.0 mM L-glutamin, 100 U/ml penicillin, 100 mg/ml streptomycin and 10% Fetal Bovine Serum (FBS) at 37°C, 5% CO<sub>2</sub>. Cells were transiently transfected with the DNA construct pIRES-GFP-Foxp3-IgG2Fc by polyfect transfection reagent (Qiagen, Germany). In brief, the transfection complex was prepared according to the optimized amount of plasmid and polyfect reagent mentioned in manufacturer instruction and transferred to 80% confluent HEK-293 cells.

At 72 hr post-transfection, transfected cells were either assessed for fluorescence microscopy analysis and flowcytometry or subjected to lysis with the mixture of 0.1 M Tris-Cl (pH=7.8) and 0.5% (V/V) Triton X-100.

#### Gene expression assays

**Fluorescent microscopy and flowcytometry analysis:** At 72 hr post-transfection, the fluorescence of transfected cells was analyzed with a Zeiss Axioskop fluorescence microscope and non-transfected cells were used as the negative control.

At the same time, trypsinized cells were analyzed for GFP emission after gating on live population by means of Partec (PAS) cytometer instrument and Flow-Max software (Partec, Germany).

#### Western-blotting

Cell lysates were separated in 12% SDS-PAGE under reducing condition, transferred to 0.45 μm pore size polyvinylidene difluoride (PVDF) membrane (Hibond Amersham Biosciences, USA) by using a semi-dry blotter unit (Biorad, USA) and blocked by 5% Bovine Serum Albumin (BSA). Subsequently, membrane was incubated with goat anti-mouse immunoglobulin G (heavy and light chain) Horseradish Peroxidase (HRP) conjugate antibody (Sigma, USA) for one hr at room temperature. The antibody was diluted 1:5000 in BSA. Detection of the protein was achieved with 3,3-diaminobenzidine tetrahydrochloride (DAB) reagent (Sigma, Saint Louis, MO, USA) and placement in darkness. Lysate of non-transfected cells served as the negative control.

The similar steps were done to confirm the expression of recombinant FoxP3-IgG2Fc fusion protein in bacterial host as well.

#### Expression and purification of Foxp3-IgG2Fc recombinant protein

To express the recombinant Foxp3-Fc(IgG) fusion protein, pET21-FoxP3-IgG2Fc plasmid was transformed into competent *E. coli* BL21(DE3) and transformed cells were grown at 37°C in LB medium supplemented with 50 μg/ml ampicillin (MERCK) up to exponential phase (OD<sub>600 nm</sub>=0.5), followed by induction of 1 mM IPTG. Samples were collected 3 hr, 5 hr and overnight post induction and the cell pellets were analyzed by SDS-PAGE to follow the best time point of protein expression. Electrophoresis of protein



samples was followed by floating the gel in sodium carbonate solution (0.08 M). Then the gel was pretreated in imidazole-SDS solution [200 mM imidazole, 0.1% (m/V) SDS followed by developing in 200 mM zinc sulfate] until the gel background turned intensely white with transparent protein bands. As development of background continued for a few seconds after the developer was discarded, the reaction was best stopped just as the bands of interest became visible. Then the band of interest was cut and homogenized in protein extraction buffer (ammonium carbonate and SDS) and was agitated overnight on the rocker. The suspension was centrifuged (20 min, 4°C, 3800 rpm) and the supernatant was collected to be concentrated by Viva spin concentrator tubes (Sartorius, Germany) with 3 kD cut off. Protein concentration was determined by Nano drop analyzer (Thermo scientific, nanodrop1000 spectrophotometer, USA) and the purity was determined by SDS-PAGE and Coomassie Brilliant Blue (R-250) staining.

## Results

### Construction of DNA plasmids that encode truncated FoxP3-IgG2Fc fusion

The truncated Foxp3 fragment was amplified by PCR on pEGFP-N1-FoxP3 using specific primers. A 1% agarose gel was run to confirm the existence of proper size of PCR product and only a single band was appeared with an estimated size of ~1114 base pairs (Figure 2). The double digested PCR product NheI-FoxP3-BglII was cloned into pIRES2-EGFP-Igk-IL18-IgG2Fc plasmid to replace IL18 with FoxP3 and made pIRES2-EGFP-FoxP3-IgG2Fc plasmid with total size of 7058 bps (Figure 1A). Then the construct was subsequently transformed into competent *E. coli* DH5α cells. The resultant colonies were evaluated for the true insert size by colony PCR method, two different enzymatic digestions (Figure 3) and PCR on colony extracted plasmids.




Figure 2. Agarose gel electrophoresis of the PCR amplified fragment. From left to right, Lane 1: negative control, Lane 2: PCR product, Lane3: DNA marker 1 Kb (Fermentase).




Figure 3. Restriction analysis of the pIRES2-EGFP-FoxP3-IgG2Fc construct with two different enzymatic cocktails. Lane 2: DNA marker 1 Kb (Fermentase), Lane 1 and 3: digested forms of the recombinant plasmid by HindIII/BglII and NheI/BglII enzymatic cocktail, respectively.

PCR reaction on pIRES2-EGFP-FoxP3-IgG2Fc plasmid using F2/R2 primer pair created the FoxP3-IgG2Fc fragment with size of 1830 bps (Figure 4A). Then the double digested PCR products and Pet21a vector were ligated together (Figure 1B) at a molar ratio of 6:1 and subsequently transformed into competent *E. coli* DH5α cells. The resultant colonies were evaluated with the same methods as previous ones. Figure 4B indicates enzymatic digestion of pET21a-Foxp3-IgG2Fc construct with two restriction enzymes *EcoRI* and *HindIII*. In the next step, recombinant vector, pet21a-Foxp3-IgG2Fc (Figure 4C), was applied for the transformation of *E. coli* BL21 (DE3) cells. The accuracy of FoxP3-Fc fusion gene in pIRES2-EGFP-FoxP3-IgG2Fc and pET21a-Foxp3-IgG2Fc plasmids was confirmed by sequencing reactions (Data not shown).

### Eukaryotic expression of recombinant FoxP3-IgG2Fc

The pIRES2-EGFP-FoxP3-IgG2Fc plasmid expressed FoxP3-IgG2Fc fusion protein and additionally was encoded for GFP as a separate protein. Fluorescence microscopy of transfected HEK 293 cells versus non-transfected ones roughly showed the expression of GFP protein (Figures 5A and 5B). Furthermore, flow cytometric analysis quantified GFP-emitting cells as 40% of the live population (Figures 5C and 5D) with mean fluorescence intensity (MFI) of 29 (for GFP positive population) versus 0.6 (for GFP negative population). This EGFP emission at least confirmed the successful transcription of GFP-FoxP3-IgG2Fc mRNA, which is an indirect indicator for FoxP3-IgG2Fc expression. To have a direct assessment of protein expression, lysates of HEK 293 cells transfected with pIRES2-EGFP-FoxP3-IgG2Fc plasmid were analyzed by western blotting. Results indicated the *ex vivo* expression of the FoxP3-IgG2Fc fusion protein with the expected size of around 69 kDa in HEK 293 cells (Figure 5D). These data confirm that pIRES-EGFP-FoxP3-IgG2Fc plasmid properly expresses the FoxP3-IgG2Fc protein *ex vivo*, and hence, is qualified to be tested as a




Figure 4. A) Agarose gel electrophoresis of the PCR amplified fragment. From left to right, Lane1: DNA marker 1 Kb (Fermentase), Lane 2: PCR product; B) restriction analysis of the pET21a-Foxp3-IgG2 (Fc) construct. From left to right, Lane 1: DNA marker 100 bp (Fermentase), Lane 2: digested form of the recombinant plasmid by BglII enzyme; C) schematic representation of the expression elements in the pET21a-Foxp3-IgG2(Fc) plasmid. TheFoxp3-IgG2(Fc) nucleotide sequence was ligated into the BglII/HindIII sites of the pET21a plasmid. This cloning strategy permitted to fuse highly efficient Ribosome Binding Site from the phage T7 major capsid protein and T7 tag to the N-terminal and 6xHis tag to the C-terminal of the Foxp3-IgG2 (Fc) fragment.

DNA vaccine plasmid for *in vivo* expression of this fusion protein.

#### Prokaryotic expression and purification of recombinant Foxp3-IgG2Fc fusion protein

*E. coli* BL21 (DE3) cells that were transformed with pET21a-FoxP3-IgG2Fc construct were induced for protein expression by adding IPTG. Lysates from induced and non-induced cells were then separated using SDS-PAGE. After staining of proteins, a band with an approximate size of ~69 kDa on lane of the induced samples was expected to be the protein of interest (Figure 6A).

In order to determine which time course of induction resulted in a higher protein production level, the same amount of IPTG, 1 mM, was added to cultures (OD 600 0.4-0.6) and at different time points of 3 hr, 5 hr and overnight post-induction, production levels of target protein were quantified. The optimal amount of rFoxp3-IgG2Fc was attained over the period of 3hrs after induction with IPTG (Figure 6B).




Figure 5. A) Evaluation of transient transfection of pIRES2-EGFP-FoxP3-IgG2Fc in HEK 293T cells compared to B) non-transfected (negative control) using fluorescent microscopy (100X) and C, D) dot-plot and histogram views of flow cytometric analysis for GFP expression in non-transfected (control) compared to transfected cells, respectively; E) assessment of the expression for FoxP3-IgG2 (Fc) fusion protein in cell lysates of pIRES2-EGFP-FoxP3-IgG2Fc transfected HEK 293T cells was carried out by using anti-Fc(IgG) polyclonal antibody. Lane 1: negative control, Lane 2: the band for fusion protein of interest with the size of 69 kDa (indicated arrow), Lane 3: protein MW marker.

#### Purification and confirmation of recombinant Foxp3-IgG-2Fc

Therefore, the high expression level of rFoxp3-IgG-2Fc was obtained when rFoxp3-IgG2Fc expressing *E. coli* BL21(DE3) cells were grown at 37 °C in LB broth supplemented with 50 µg/ml ampicillin and induction of cells were conducted with 1 mM IPTG after the OD 600 nm reached 0.6. The optimal expression level was found to be achieved 3 hr after the addition of IPTG to the medium. Recombinant protein was purified by Imidazole-SDS-Zinc reverse staining. Theoretical molecular weight of target protein was measured ~69 kDa. The 69 kDa protein band was observed in SDS-PAGE

## Production of Foxp3- Fc (IgG) Fusion Protein




Figure 6. A) SDS-PAGE analysis of recombinant Foxp3-IgG2 (Fc) with Coomassie-stained. Expression of rFoxp3-IgG2 (Fc) in *E coli* BL21 induced with 1.0 mmol IPTG. From left to right: Lane 1: Protein marker (Fermentase), Lane 2: Non-induced with IPTG, Lane 3: Induced with IPTG (~69 kDa), Lane 4: Bacterial lysate (negative control); B) the effect of the period of induction on high production level of rFoxp3- IgG2(Fc). Triplicate lanes induced with 1mM IPTG (showed by arrows), uninduced and protein marker at time course of induction 3 hr, 5 hr and overnight, respectively.




Figure 7. A) Purification of rFoxp3- IgG2 (Fc) by Imidazole-SDS-Zinc reverse staining. From left to right: Lane 1: transformed bacterial lysate induced by IPTG which was run in a wide lane and shown by arrow, Lane 2: protein marker; B) western blot analysis. From left to right, Lane 1: induced *E. coli* BL21 containing Pet21a-FoxP3-IgG2(Fc), Lane 2: negative control, Lane 3: protein marker.

and it was confirmed as rFoxp3- IgG2Fc protein by western blot analysis using goat anti-mouse antibody (Figures 7A and 7B).

Overall, these data confirm that pET21-FoxP3-IgG2Fc plasmid can be efficiently used in an optimized system for preparative expression and purification of truncated FoxP3-IgG2Fc protein for further aims of animal immunization and vaccine studies.

### Sequence analysis of recombinant Foxp3- IgG2Fc

The final nucleotide sequence for constructed FoxP3-IgG2Fc was 98% matched with the expected nucleotide sequence. However, the amino acid translation of this sequence was completely (100%) matched with the expected amino acid sequence for truncated FoxP3-IgG2Fc protein (Data not shown).

### Discussion

The application of DNA vaccine and its respective recombinant protein production in biotechnology have been increased in experimental and clinical designs. However, high efficiency of DNA vaccines and recombinant proteins in experimental systems is an issue. Therefore, different methods including fusion with different partners have been developed to improve their effectiveness.

Due to their rapid and widespread development, DNA vaccines have entered into a variety of human clinical trials for vaccination against various diseases including cancer. The results of previous studies in clinical trial have shown that such DNA vaccines require much improvement in antigen expression and delivery methods to make them sufficiently effective in the clinic. Similarly, additional strategies should be employed to activate effective immunity against poorly immunogenic tumor antigens. Engineering vaccine design for manipulating antigen presentation and processing pathways is one of the most important aspects that can be easily handled in DNA vaccine technology<sup>23</sup>. Several approaches have been investigated including DNA vaccine engineering, co-delivery of immunomodulatory molecules, safe routes of administration, prime-boost regimen and strategies to break the immunosuppressive network mechanisms adopted by malignant cells to prevent immune cell function<sup>24</sup>. Combined or single strategies to enhance the efficacy and immunogenicity of DNA vaccines are applied in completed and ongoing clinical trials, where the safety and tolerability of the DNA platform are substantiated<sup>23-26</sup>.

APCs are critical for initiating and modulating B- and T-cell responses elicited by DNA vaccination. However, only a very limited fraction of injected DNA molecules are taken up by APCs in draining lymph nodes<sup>27</sup>. Even when DCs are transfected, the intracellular antigens expressed by DCs are difficult to be processed and presented to MHC class II<sup>10</sup>. Even secretory antigens cannot be efficiently presented to MHC class I and II because of the inefficiency of internalization of soluble antigens through fluid phase pinocytosis<sup>20</sup>. In this study, antigen-Fc fusion protein was constructed which aids receptor-mediated internalization process to enhance APC antigen presentation and increase immune responses, especially CD4+T cells. Although there have been attempts to target an antigen to APCs to enhance the potency of DNA vaccines,



such as using Cytotoxic T-Lymphocyte-Associated protein 4 (CTLA4) molecule<sup>28,29</sup>, the vaccine design described has some unique features. Fc portion enables receptor-mediated endocytosis pathway, permits fusion antigens to be efficiently captured, processed in endosomes, and presented to MHC by APC to induce T cell responses<sup>20</sup>.

As described in this project, DNA construct containing Fc portion of IgG fused to Foxp3 was designed in pIRES-EGFP plasmid. The expression of DNA construct was investigated by transfection of HEK cells with this DNA construct.

It has been reported that combination of tumor antigen expressing vector and plasmids containing other proteins such as adjuvants (to improve immune responses) could ameliorate antitumor reactions *in vivo*<sup>24</sup>. Moreover, some reports have shown that presence of bicistronic vectors is also helpful for efficiency of gene adjuvants<sup>30</sup>. One of the characteristics of these vectors is production of single long mRNA from two different expressing regions under the control of a single promoter. In this mRNA, the first protein is translated under CAP-dependent mechanism and the second is produced using IRES<sup>30</sup>. In some researches on positive role of adjuvants in improved induction of immune response, it has been shown that expression of both tumor antigen and adjuvant by single plasmid could cause more powerful immune responses<sup>31</sup>. In other words, a good stimulation of lymphocytes is following co-presentation of antigen and adjuvant by antigen presenting cells<sup>32</sup>. Using adjuvants with tumor antigens in combination with distinguished immunotherapy means is considered as a combinatorial therapy<sup>5</sup>.

FoxP3-IgG2Fc fusion construct and protein produced in this study targets regulatory T cells which are an obstacle against efficient anti-tumor responses. Therefore, combination of the present FoxP3-IgG2Fc fusion system and other conventional immunotherapies seems encouraging to attain effective, reliable and consistent clinical efficacy. In the present study, truncated FoxP3 gene fused to IgG2Fc was amplified and cloned into pIRES2-EGFP and pET21a vectors successfully. Subsequently, *ex vivo* performance of both vectors was checked in prokaryotic and eukaryotic expression systems, respectively. Thus, it is required to go further to test our constructs *in vivo* and see whether they can induce a functional immune response against T regs.

### Conclusion

In summary, the cloning and expression vectors containing FoxP3-IgG2Fc fragment were constructed as DNA vaccine and recombinant protein producing vector. As the prepared vectors worked properly *ex vivo*, they seem to be suitable for application in designing experimental studies to conquer regulatory T cells suppressive effects in tumor immune responses.

### Acknowledgement

This work was supported by Department of Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Science, Department of Hepatitis and AIDS, Pasteur Institute of Iran, Department of Immunology, Faculty of Medicine, Tehran University of Medical Science and Iran National Science Foundation (INSF).

### References

1. Powell DJ Jr, Felipe-Silva A, Merino MJ, Ahmadzadeh M, Allen T, Levy C, et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells *in vivo*. *J Immunol* 2007;179(7):4919-4928.
2. Vergati M, Schlom J, Tsang KY. The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring. *J Biomed Biotechnol* 2011;2011:182413.
3. Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. *Cancer Res* 2007;67(1):371-380.
4. Orentas RJ, Kohler ME, Johnson BD. Suppression of anti-cancer immunity by regulatory T cells: back to the future. *Semin Cancer Biol* 2006;16(2):137-149.
5. Zou W. Regulatory T cells, tumour immunity and immunotherapy. *Nat Rev Immunol* 2006;6(4):295-307.
6. Sheu BC, Chang WC, Huang SC. New era of regulatory T cells in tumor immunity: insights in cancer immunotherapy. *J Formos Med Assoc* 2010;109(1):1-3.
7. Wang HY, Wang RF. Antigen-specific CD4+ regulatory T cells in cancer: implications for immunotherapy. *Microbes Infect* 2005;7(7-8):1056-1062.
8. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. *Blood* 2008;112(3):610-618.
9. Generali D, Bates G, Berruti A, Brizzi MP, Campo L, Bonardi S, et al. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. *Clin Cancer Res* 2009;15(3):1046-1051.
10. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. *Annu Rev Immunol* 1997;15(1):821-850.
11. Greten TF, Ormandy LA, Fikuart A, Höchst B, Henschen S, Hörning M, et al. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. *J Immunother* 2010;33(2):211-218.
12. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. *Blood* 2005;105(7):2862-2868.

13. Rosalia RA, Štěpánek I, Polláková V, Šimová J, Biebová J, Indrová M, et al. Administration of anti-CD25 mAb leads to impaired alpha-galactosylceramide-mediated induction of IFN-gamma production in a murine model. *Immunobiology* 2013;218(6):851-859.
14. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. *Ann N Y Acad Sci* 2009;1174:99-106.
15. Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C. IL-2 immunotoxin denileukin diftotox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. *Blood* 2007;110(9):3192-3201.
16. Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF, et al. Selective depletion of Foxp3<sup>+</sup> regulatory T cells improves effective therapeutic vaccination against established melanoma. *Cancer Res* 2010;70(20):7788-7799.
17. Mattarollo SR, Steegh K, Li M, Duret H, Ngiow SF, Smyth MJ. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells. *Immunol Cell Biol* 2013;91(1):105-114.
18. Flanagan ML, Arias RS, Hu P, Khawli LA, Epstein AL. Soluble Fc fusion proteins for biomedical research. *Methods Mol Biol* 2007;378:33-52.
19. Guyre PM, Graziano RF, Goldstein J, Wallace PK, Morganelli PM, Wardwell K, et al. Increased potency of Fc-receptor-targeted antigens. *Cancer Immunol Immunother* 1997;45(3-4):146-148.
20. You Z, Huang X, Hester J, Toh HC, Chen SY. Targeting dendritic cells to enhance DNA vaccine potency. *Cancer Res* 2001;61(9):3704-3711.
21. Dorgham K, Abadie V, Iga M, Hartley O, Gorochoy G, Combadière B. Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination. *Vaccine* 2008;26(26):3252-3260.
22. Pouriayeali MH, Memarnejadian AR, Sadat M, Zavva M, Siadat SD, Hartoonian C, et al. Designing and construction of bicistronic plasmid pIRES-Igk/mIL 18/Fc potential implications for vaccine investigations. *Modarres J Med Sci: Pathobiol* 2011;14(2):13-23.
23. Abdulhaqq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. *Immunol Res* 2008;42(1-3):219-232.
24. Fioretti D, Iurescia S, Fazio VM, Rinaldi M. DNA vaccines: developing new strategies against cancer. *J Biomed Biotechnol* 2010;2010:174378.
25. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? *Nat Rev Genet* 2008;9(10):776-788.
26. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. *Nat Rev Cancer* 2008;8(2):108-120.
27. Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. *J Exp Med* 1999;189(1):169-178.
28. Boyle JS, Brady JL, Lew AM. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. *Nature* 1998;392(6674):408-411.
29. Deliyannis G, Boyle JS, Brady JL, Brown LE, Lew AM. A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge. *Proc Natl Acad Sci USA* 2000;97(12):6676-6680.
30. Chambard JC, Pognonec P. A reliable way of obtaining stable inducible clones. *Nucleic Acids Res* 1998;26(14):3443-3444.
31. Chang SY, Lee KC, Ko SY, Ko HJ, Kang CY. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. *Int J cancer* 2004;111(1):86-95.
32. Barouch DH, Santra S, Tenner-Racz K, Racz P, Kuroda MJ, Schmitz JE, et al. Potent CD4<sup>+</sup> T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. *J Immunol* 2002;168(2):562-568.